Trial Profile
A retrospective study evaluating the efficacy of combining Venetoclax with either azacitidine, decitabine, or low-dose cytarabine in patients with acute myeloid leukemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Cytarabine; Decitabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia
- Focus Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results (n=21) assessing efficacy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology